LARP1B

Summary

LARP1B (La ribonucleoprotein 1B, HGNC:24704) is a protein-coding gene on chromosome 4q28.2, encoding La-related protein 1B (Q659C4).

This gene encodes a protein containing domains found in the La related protein of Drosophila melanogaster. La motif-containing proteins are thought to be RNA-binding proteins, where the La motif and adjacent amino acids fold into an RNA recognition motif. The La motif is also found in proteins unrelated to the La protein. Alternative splicing has been observed at this locus and multiple variants, encoding distinct isoforms, are described. Additional splice variation has been identified but the full-length nature of these transcripts has not been determined.

Source: NCBI Gene 55132 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 158 total
• MANE Select transcript: NM_018078

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24704
Approved symbol	LARP1B
Name	La ribonucleoprotein 1B
Location	4q28.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10378, DKFZp434K245, DKFZp686E0316
Ensembl gene	ENSG00000138709
Ensembl biotype	protein_coding
OMIM	620467
Entrez	55132

Gene structure

Transcript identifiers

Ensembl transcripts: 30 — 25 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000326639, ENST00000394288, ENST00000432347, ENST00000503725, ENST00000506199, ENST00000507259, ENST00000507377, ENST00000508648, ENST00000508819, ENST00000512292, ENST00000648358, ENST00000649983, ENST00000650359, ENST00000704292, ENST00000704293, ENST00000899913, ENST00000899914, ENST00000899915, ENST00000899916, ENST00000899917, ENST00000899918, ENST00000899919, ENST00000899920, ENST00000899921, ENST00000917667, ENST00000917668, ENST00000917669, ENST00000952429, ENST00000952430, ENST00000952431

RefSeq mRNA: 6 — MANE Select: NM_018078 NM_001278604, NM_001350531, NM_001410786, NM_018078, NM_032239, NM_178043

CCDS: CCDS3738, CCDS47133, CCDS64057, CCDS93633

Canonical transcript exons

ENST00000326639 — 20 exons

Exon	Start	End
ENSE00001249220	128074460	128074518
ENSE00001818636	128209856	128211988
ENSE00002037457	128061312	128061401
ENSE00003459303	128082165	128082305
ENSE00003463054	128176872	128176907
ENSE00003463427	128200521	128200665
ENSE00003480408	128121826	128122188
ENSE00003481638	128207256	128207383
ENSE00003495631	128199439	128199599
ENSE00003503717	128178431	128178642
ENSE00003504100	128179406	128179512
ENSE00003526995	128074934	128074993
ENSE00003548310	128098186	128098330
ENSE00003582489	128107139	128107313
ENSE00003588492	128162194	128162317
ENSE00003620489	128077788	128077962
ENSE00003649980	128114570	128114742
ENSE00003669622	128091347	128091512
ENSE00003674312	128206428	128206537
ENSE00003689147	128091001	128091144

Expression profiles

Bgee: expression breadth ubiquitous, 252 present calls, max score 94.74.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.5681 / max 545.6951, expressed in 1811 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
49619	17.3386	1803
49620	5.1731	1570
49622	0.4114	147
49618	0.3247	121
49616	0.1173	54
49617	0.0841	37
49615	0.0742	36
49621	0.0211	4
49625	0.0199	3
49626	0.0036	1

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	94.74	gold quality
sperm	CL:0000019	94.19	gold quality
body of pancreas	UBERON:0001150	93.81	gold quality
left testis	UBERON:0004533	92.88	gold quality
right testis	UBERON:0004534	92.51	gold quality
right lobe of liver	UBERON:0001114	92.39	gold quality
pancreas	UBERON:0001264	92.14	gold quality
epithelial cell of pancreas	CL:0000083	91.83	gold quality
calcaneal tendon	UBERON:0003701	91.49	gold quality
testis	UBERON:0000473	91.38	gold quality
oocyte	CL:0000023	90.81	gold quality
liver	UBERON:0002107	90.59	gold quality
islet of Langerhans	UBERON:0000006	90.46	gold quality
bone marrow cell	CL:0002092	90.21	gold quality
tendon	UBERON:0000043	89.67	gold quality
oviduct epithelium	UBERON:0004804	87.70	gold quality
rectum	UBERON:0001052	87.58	gold quality
gastrocnemius	UBERON:0001388	87.12	gold quality
sural nerve	UBERON:0015488	87.03	gold quality
colonic epithelium	UBERON:0000397	86.81	gold quality
muscle of leg	UBERON:0001383	86.64	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.53	gold quality
corpus epididymis	UBERON:0004359	86.00	gold quality
ventricular zone	UBERON:0003053	85.79	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.65	gold quality
tibial artery	UBERON:0007610	85.51	gold quality
popliteal artery	UBERON:0002250	85.50	gold quality
body of stomach	UBERON:0001161	84.91	gold quality
buccal mucosa cell	CL:0002336	84.65	silver quality
left ventricle myocardium	UBERON:0006566	84.59	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	15.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

77 targeting LARP1B, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-429	100.00	73.44	2698
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-200B-3P	100.00	73.31	2693
HSA-MIR-200C-3P	100.00	73.35	2685
HSA-MIR-568	99.98	69.86	2084
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-302A-3P	99.89	71.23	1777
HSA-MIR-302B-3P	99.89	71.23	1777
HSA-MIR-302C-3P	99.89	71.20	1778
HSA-MIR-302D-3P	99.89	71.25	1777
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-548AR-3P	99.85	71.26	3889
HSA-MIR-373-3P	99.84	70.68	1668
HSA-MIR-520E-3P	99.84	70.55	1698
HSA-MIR-372-3P	99.83	70.58	1691
HSA-MIR-520A-3P	99.83	70.59	1687
HSA-MIR-520B-3P	99.83	70.56	1699
HSA-MIR-520C-3P	99.83	70.56	1699
HSA-MIR-520D-3P	99.83	70.78	1676
HSA-MIR-548E-3P	99.82	70.59	3514
HSA-MIR-520F-3P	99.82	71.32	1216
HSA-MIR-548AZ-3P	99.82	70.56	3549
HSA-MIR-548BC	99.82	70.61	3524
HSA-MIR-548F-3P	99.82	70.59	3540
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248

Literature-anchored findings (GeneRIF, showing 2)

• Review discusses the La motif, found in this protein. (PMID:12045101)
• The promoter of the gene of La ribonucleoprotein domain family (LARP2) was significantly hypermethylated in beta-thalassemia, and the expression of LARP2 was significantly lower in beta-thalassemia. (PMID:22327645)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	larp1b	ENSDARG00000061169
mus_musculus	Larp1b	ENSMUSG00000025762
rattus_norvegicus	Larp1bl	ENSRNOG00000013940
rattus_norvegicus	Larp1b	ENSRNOG00000038366
drosophila_melanogaster	Larp4B	FBGN0035424
drosophila_melanogaster	larp	FBGN0261618
caenorhabditis_elegans	larp-5	WBGENE00004147
caenorhabditis_elegans		WBGENE00020097

Paralogs (6): LARP4B (ENSG00000107929), SSB (ENSG00000138385), LARP1 (ENSG00000155506), LARP4 (ENSG00000161813), LARP6 (ENSG00000166173), LARP7 (ENSG00000174720)

Protein

Protein identifiers

La-related protein 1B — Q659C4 (reviewed: Q659C4)

Alternative names: La ribonucleoprotein domain family member 1B, La ribonucleoprotein domain family member 2, La-related protein 2

All UniProt accessions (10): A0A3B3ISF0, A0A3B3IT29, A0A994J4H9, A0A994J4X5, D6R9W6, D6RJB0, Q659C4, G3V0E9, H0Y9B4, H0Y9K3

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the LARP family.

Isoforms (9)

UniProt ID	Names	Canonical?
Q659C4-1	1	yes
Q659C4-2	2
Q659C4-3	3
Q659C4-4	4
Q659C4-5	5
Q659C4-6	6
Q659C4-7	7
Q659C4-8	8
Q659C4-9	9

RefSeq proteins (6): NP_001265533, NP_001337460, NP_001397715, NP_060548, NP_115615, NP_835144 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006607	DM15	Repeat
IPR006630	La_HTH	Domain
IPR036388	WH-like_DNA-bd_sf	Homologous_superfamily
IPR036390	WH_DNA-bd_sf	Homologous_superfamily
IPR045180	La_dom_prot	Family

Pfam: PF05383, PF21071

UniProt features (51 total): splice variant 16, compositionally biased region 11, modified residue 10, sequence conflict 6, region of interest 4, sequence variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q659C4-F1	56.94	0.14

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 60, 327, 329, 335, 340, 343, 427, 432, 436, 454

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 118 (showing top): RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, GOBP_REGULATION_OF_MRNA_CATABOLIC_PROCESS, GCANCTGNY_MYOD_Q6, AREB6_03, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_UP, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_TRANSLATION, GOBP_POST_TRANSCRIPTIONAL_REGULATION_OF_GENE_EXPRESSION, MYOD_01, GOBP_REGULATION_OF_CATABOLIC_PROCESS, MYOD_Q6, AACTTT_UNKNOWN, MORI_PLASMA_CELL_UP, TAATGTG_MIR323, E12_Q6

GO Biological Process (2): positive regulation of translation (GO:0045727), mRNA stabilization (GO:0048255)

GO Molecular Function (3): RNA cap binding (GO:0000339), RNA binding (GO:0003723), protein binding (GO:0005515)

GO Cellular Component (4): nucleus (GO:0005634), cytosol (GO:0005829), cytoplasmic stress granule (GO:0010494), ribonucleoprotein complex (GO:1990904)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
translation	1
regulation of translation	1
positive regulation of gene expression	1
positive regulation of protein metabolic process	1
regulation of mRNA stability	1
RNA stabilization	1
negative regulation of mRNA catabolic process	1
RNA binding	1
nucleic acid binding	1
binding	1
intracellular membrane-bounded organelle	1
cytoplasm	1
cellular anatomical structure	1
cytoplasmic ribonucleoprotein granule	1
protein-containing complex	1

Protein interactions and networks

STRING

1490 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
LARP1B	PGRMC2	O15173	545
LARP1B	AGO2	Q9UKV8	462
LARP1B	SYNDIG1L	A6NDD5	454
LARP1B	SPMIP10	Q6ZNM6	447
LARP1B	EDRF1	Q3B7T1	440
LARP1B	ABHD18	Q0P651	436
LARP1B	SLC25A31	Q9H0C2	426
LARP1B	CYB5D2	Q8WUJ1	417
LARP1B	KRT77	Q7Z794	407
LARP1B	JADE1	Q6IE81	395
LARP1B	SH3RF3	Q8TEJ3	393
LARP1B	KIAA1210	Q9ULL0	393
LARP1B	ZCCHC13	Q8WW36	387
LARP1B	RRP12	Q5JTH9	385
LARP1B	GTF2A1	P52655	381

IntAct

157 interactions, top by confidence:

A	B	Type	Score
N	HNRNPR	psi-mi:“MI:0914”(association)	0.730
H2AX	PPM1G	psi-mi:“MI:0914”(association)	0.730
LIN28A	IGF2BP3	psi-mi:“MI:0914”(association)	0.640
LARP1B	KIF2A	psi-mi:“MI:0915”(physical association)	0.560
LARP1B	TRIM69	psi-mi:“MI:0915”(physical association)	0.560
KIF2A	LARP1B	psi-mi:“MI:0915”(physical association)	0.560
TRIM69	LARP1B	psi-mi:“MI:0915”(physical association)	0.560
NP	KPNA6	psi-mi:“MI:0914”(association)	0.550
N	RBM47	psi-mi:“MI:0914”(association)	0.530
SNRNP70	GTPBP1	psi-mi:“MI:0914”(association)	0.530
ELAVL2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
GSPT2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
THAP3	CASC3	psi-mi:“MI:0914”(association)	0.530
PAIP2B	CASC3	psi-mi:“MI:0914”(association)	0.530
ZFC3H1	HNRNPCL1	psi-mi:“MI:0914”(association)	0.530
IGF2BP3	PTCD1	psi-mi:“MI:0914”(association)	0.530
NIFK	RSL1D1	psi-mi:“MI:0914”(association)	0.530
CCNI2	HSPA8	psi-mi:“MI:0914”(association)	0.530
ILF2	IGF2BP3	psi-mi:“MI:0914”(association)	0.530
GSK3B	SEC16A	psi-mi:“MI:2364”(proximity)	0.420
LARP1B	H4C16	psi-mi:“MI:0915”(physical association)	0.400
	FER1L5	psi-mi:“MI:0915”(physical association)	0.400
LARP1B	POLR2J	psi-mi:“MI:0915”(physical association)	0.370
LARP1B	BKLF1	psi-mi:“MI:0915”(physical association)	0.370
Rpl35	RPS6	psi-mi:“MI:0914”(association)	0.350
NP	KPNA4	psi-mi:“MI:0914”(association)	0.350

BioGRID (176): LARP1B (Two-hybrid), TRIM69 (Two-hybrid), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1B (Proximity Label-MS), LARP1B (Two-hybrid), LARP1B (Affinity Capture-MS), LARP1B (Affinity Capture-MS), LARP1 (Affinity Capture-MS)

ESM2 similar proteins: A0A8M2, A0JMU8, A1L1K8, A5D7H5, B9DFV2, E1BUG7, F4JP52, G1SW77, G3X9Z4, O08719, O15234, O94913, Q0V898, Q1LVV0, Q2T9I5, Q32NW2, Q3MHF8, Q498K9, Q566L7, Q5CZI8, Q5JVS0, Q5R4R4, Q5T8P6, Q5TYQ8, Q659C4, Q68FI1, Q6AXS5, Q6NVR8, Q6NZN0, Q6PKG0, Q8AVJ2, Q8CGC4, Q8K2F8, Q8K3W3, Q8K3X0, Q8NC51, Q8ND56, Q91W18, Q91W39, Q96D71

Diamond homologs: D5MCN2, J9VT60, O80567, P05455, P10881, P25567, P28048, P28049, P32067, P33399, P38656, P40796, Q05CL8, Q12034, Q26457, Q28G87, Q4G0J3, Q4R627, Q5XI01, Q659C4, Q6PKG0, Q6ZQ58, Q71RC2, Q7ZWE3, Q8BN59, Q8BWW4, Q8RWR2, Q94A38, Q94K80, Q9BRS8, Q9I7T7, Q9LHL3, Q9P6K0, Q9VAW5, Q940X9, P87058, Q04504, A8NS61, A8WLV5, B4NB54

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 154 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	6	26.9×	7e-06
RNA Polymerase II Transcription Termination	6	15.5×	1e-04
Influenza Infection	7	14.5×	3e-05
mRNA 3’-end processing	6	13.9×	2e-04
Influenza Viral RNA Transcription and Replication	5	12.7×	1e-03
Transport of Mature mRNA derived from an Intron-Containing Transcript	7	12.5×	7e-05
SARS-CoV-1-host interactions	6	12.4×	3e-04
mRNA Splicing	9	11.6×	7e-06

GO biological processes:

GO term	Partners	Fold	FDR
mRNA stabilization	6	16.2×	5e-04
ribosomal small subunit biogenesis	7	11.7×	5e-04
RNA processing	7	11.3×	5e-04
regulation of alternative mRNA splicing, via spliceosome	6	10.8×	2e-03
mRNA transport	5	9.7×	8e-03
cytoplasmic translation	7	9.5×	1e-03
rRNA processing	7	7.3×	3e-03
RNA splicing	9	5.8×	2e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

158 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	130
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4362 predictions. Top by Δscore:

Variant	Effect	Δscore
4:128074458:A:AG	acceptor_gain	1.0000
4:128074459:G:GG	acceptor_gain	1.0000
4:128074514:ACAAG:A	donor_loss	1.0000
4:128074515:CAAG:C	donor_loss	1.0000
4:128074516:AAG:A	donor_loss	1.0000
4:128074517:AGGT:A	donor_loss	1.0000
4:128074518:GGT:G	donor_loss	1.0000
4:128074519:G:C	donor_loss	1.0000
4:128074520:T:G	donor_loss	1.0000
4:128074933:GGCTA:G	acceptor_gain	1.0000
4:128074989:CTGGA:C	donor_gain	1.0000
4:128074990:TGGA:T	donor_gain	1.0000
4:128074991:GGA:G	donor_gain	1.0000
4:128074991:GGAG:G	donor_gain	1.0000
4:128074992:GA:G	donor_gain	1.0000
4:128074992:GAG:G	donor_gain	1.0000
4:128074993:AG:A	donor_loss	1.0000
4:128074994:G:GG	donor_gain	1.0000
4:128074994:GT:G	donor_loss	1.0000
4:128074995:TGAGT:T	donor_loss	1.0000
4:128074996:G:GG	donor_loss	1.0000
4:128074997:AG:A	donor_loss	1.0000
4:128074998:G:T	donor_loss	1.0000
4:128077783:T:A	acceptor_gain	1.0000
4:128077786:A:AG	acceptor_gain	1.0000
4:128077787:G:GT	acceptor_gain	1.0000
4:128077787:GT:G	acceptor_gain	1.0000
4:128077787:GTTT:G	acceptor_gain	1.0000
4:128077787:GTTTC:G	acceptor_gain	1.0000
4:128077954:G:GG	donor_gain	1.0000

AlphaMissense

6041 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
4:128206451:G:T	R778M	1.000
4:128207268:G:A	G811E	1.000
4:128107208:T:A	W295R	0.999
4:128107208:T:C	W295R	0.999
4:128199537:T:C	L701P	0.999
4:128199554:T:C	F707L	0.999
4:128199555:T:C	F707S	0.999
4:128199556:T:A	F707L	0.999
4:128199556:T:G	F707L	0.999
4:128200525:A:C	R723S	0.999
4:128200525:A:T	R723S	0.999
4:128200566:T:C	L737P	0.999
4:128200577:T:A	W741R	0.999
4:128200577:T:C	W741R	0.999
4:128200590:T:A	L745H	0.999
4:128200590:T:C	L745P	0.999
4:128200594:A:C	R746S	0.999
4:128200594:A:T	R746S	0.999
4:128200625:T:C	F757L	0.999
4:128200626:T:C	F757S	0.999
4:128200627:T:A	F757L	0.999
4:128200627:T:G	F757L	0.999
4:128200638:C:A	A761D	0.999
4:128200665:G:T	R770M	0.999
4:128206432:G:T	G772W	0.999
4:128206433:G:A	G772E	0.999
4:128206441:T:C	C775R	0.999
4:128206443:T:G	C775W	0.999
4:128206445:T:C	L776P	0.999
4:128206447:T:C	F777L	0.999

dbSNP variants (sampled 300 via entrez): RS1000011941 (4:128095754 C>G), RS1000022508 (4:128082029 T>C), RS1000048762 (4:128124152 G>A), RS1000068431 (4:128136603 A>G), RS10000748 (4:128161336 T>A,C,G), RS1000082977 (4:128110469 C>G,T), RS1000090625 (4:128186112 A>G), RS1000094891 (4:128104987 C>T), RS10000960 (4:128161578 T>A,C,G), RS10001048 (4:128161666 T>A,C), RS1000108591 (4:128100782 GTCTTTTCATTT>G), RS1000109381 (4:128070156 A>C), RS1000134614 (4:128195856 A>C,G), RS1000149104 (4:128181486 T>A), RS1000182107 (4:128181054 C>T)

Disease associations

OMIM: gene MIM:620467 | disease phenotypes: MIM:610951

GenCC curated gene-disease

Mondo (2): neuronal ceroid lipofuscinosis 7 (MONDO:0012588), prostate cancer (MONDO:0008315)

Orphanet (3): OBSOLETE: Late infantile neuronal ceroid lipofuscinosis (Orphanet:168491), CLN7 disease (Orphanet:228366), Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST90002390_221	Mean corpuscular hemoglobin	3.000000e-27
GCST90002392_668	Mean corpuscular volume	8.000000e-25
GCST90002397_22	Mean spheric corpuscular volume	1.000000e-10
GCST90011900_90	Serum alkaline phosphatase levels	1.000000e-13
GCST90013406_35	Liver enzyme levels (alkaline phosphatase)	8.000000e-15

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004527	mean corpuscular hemoglobin
EFO:0004533	alkaline phosphatase measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750
C563989	Ceroid Lipofuscinosis, Neuronal, 7 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB variants

1 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs4834232	LARP1B		0.00	0

CTD chemical–gene interactions

64 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	decreases expression, increases methylation, affects cotreatment, increases expression, affects expression	6
sodium arsenite	decreases expression, increases abundance, increases expression	5
Cyclosporine	increases expression	4
bisphenol A	affects expression, affects methylation	2
trichostatin A	affects expression, increases expression	2
Air Pollutants	affects expression, increases abundance, increases expression	2
Arsenic	increases abundance, increases expression, decreases expression	2
Benzo(a)pyrene	decreases methylation, affects methylation, decreases expression	2
Estradiol	affects expression, increases expression	2
Tobacco Smoke Pollution	increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
dicrotophos	decreases expression	1
geldanamycin	increases expression	1
bufotalin	decreases expression	1
lead acetate	affects cotreatment, decreases expression	1
beta-lapachone	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
zinc protoporphyrin	affects cotreatment, decreases expression	1
butyraldehyde	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
pentabromodiphenyl ether	increases expression	1
K 7174	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	increases expression	1
abrine	increases expression	1
2,2’,4,4’-tetrabromodiphenyl ether	increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	decreases expression, affects cotreatment	1
PCI 5002	affects cotreatment, increases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer